Hypoglycemic peptide and drug use thereof

Abstract

The invention provides a hypoglycemic peptide, which is provided with an amino acid sequence as shown in SEQ ID NO: 1. The invention also provides a modified peptide of the hypoglycemic peptide. A chemical group, an amino acid, polypeptide, protein or PEG is connected to the N end, C end or intermediate residue of the hypoglycemic peptide. The hypoglycemic peptide provided by the invention can perfect the glucose tolerance of KK-Ay mice, reinforce the glucose utilization ability of the KK-Ay mice, significantly improve the fasting blood glucose and glucose tolerance of the KK-Ay mice, significantly reduce serum total cholesterol and serum triglyceride, significantly perfect the SOD level, reduce the MDA level and protect the body cells against oxygen free radicals, the hypoglycemic peptide has glucose and lipid reducing functions and can resist metabolic syndrome. The hypoglycemic peptide can be used for preparing drugs or healthcare products for treating and / or preventing diabetes or hyperlipidemia.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a hypoglycemic peptide and its medicinal use. Background technique [0002] Diabetes mellitus (DM) is a metabolic disease characterized by relative or absolute insufficiency of insulin and the main symptom of hyperglycemia. Relative or absolute insufficiency of insulin causes hyperglycemia, which in turn leads to metabolic disorders of the three major nutrients, ultimately affecting patients Normal physiological function and cause complications. There are many types of diabetes, with type 1 diabetes and type 2 diabetes being the most common. Traditional antidiabetic drugs have their own disadvantages. Insulin administration is inconvenient and can easily cause hypoglycemia; insulin secretagogues such as sulfonylureas, repaglinide, and nateglinide can be taken orally, but they depend on the existence of residual pancreatic β cells and are likely to cause hypoglycemia. Second...

AI Technical Summary

Problems solved by technology

Traditional antidiabetic drugs have their own disadvantages

Insulin administration is inconvenient and can easily cause hypoglycemia; insulin secretagogues such as sulfonylureas, repaglinide, and nateglinide can be taken orally, but they depend on the existence of residual pancreatic β cells and are likely to cause hypoglycemia. Secondary failure often occurs; severe adverse reactions of metformin; α-glucosidase inhibitors and thiazolidinediones cannot fundamentally lower blood sugar

The newly launched glucagon-like peptide-1 (glucose-like peptide-1, GLP-1) analogues have excellent effects on type Ⅱ diabetes mellitus, which are not well cured by traditional hypoglycemic drugs, but are unstable in nature and require high storage. Short duration of action, requires injection

Images